SÖSuat Özlük

Suat Özlük

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suat Özlük has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antiviral drug resistance rates among patients with chronic hepatitis B infection

    by Suat Özlük, Yasemin Bayram, Ayşe Özkaçmaz, Mehmet Parlak, Ayşe Özdemir, Cenk Aypak

    Introduction and aim. Chronic hepatitis B infection (CHB) affects millions of people around the world. Many clinicians find it challenging to choose therapeutic agents due to the mutations that occur in the hepatitis B virus (HBV) that cause drug resistance. Thus, the aim of this study was to determine the HBV resistance rates against the currently recommended first-line therapies in the region of our country where HBV prevalence is high. Material and methods. A total of 96 patients (56 men and 40 women) with HBV infection were enrolled in the study. The serum samples collected from those were analyzed with real-time polymerase chain reaction analysis followed by pyrosequencing (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) for drug resistance mutations associated with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. Results. HBV drug-resistance mutations were investigated in 80 treatment-naïve and 16 treatment-experienced patients (6 entecavir, 4 PEGylated-interferon, 4 tenofovir, 2 lamivudine). None of the HBV-DNA samples had mutations cause to drug resistance were detected in any codons regions that were analyzed. Conclusion. Antiviral resistance poses serious obstacles for clinicians in the treatment of CHB. Determining whether antiviral resistance exists in HBV is critical to choose the appropriate treatment agent.

  • Relationship of ABO Blood Groups to SARS-COV-2 Infection Causing COVID-19 Disease

    by Özlem Ki̇rİşCi̇, Suat Özlük, Ümmühan Su Topalca, Nazik Doğramaci Köprülü

    Objective: We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems. Methods: The clinical data of 455 patients with COVID-19 seen between April 17, 2020, and June 30, 2020, at the Necip Fazıl City Hospital were retrospectively analyzed studied. The differences in the ABO blood group distribution between COVID-19 patients and the control group (7844 cases) were analyzed. Results: The percentage of patients with type O blood in the COVID-19 group was significantly lower than that in the control group (29.7% vs. 35.6%, p = 0.009). The percentage of patients with type A and B blood in the COVID-19 set was higher than in the control group however, there were no significant differences, respectively (44.4% vs. 40.8%, 19.3% vs.16.6%, p = 0.134, p=0.123). Patients with blood group O had a lower risk of COVID-19 than A, B blood group patients (respectively; OR = 0.732, OR=0.594, p = 0.023, p=0.001). The risk of COVID-19 was higher for patients with blood groups A and B than with a blood group 0 (OR = 1.365, OR= 1.684, p = 0.023, p=0.001). The Rh blood group phenotype was not statistically significant in determining a patient’s vulnerability. Conclusion: The results of the present study suggest that while the blood group 0 had a low risk and decreased risk for infection with SARS-CoV-2, whereas blood group A and B were associated related with an increased risk, indicating that certain specific ABO blood groups were connected correlated with SARS-CoV-2 susceptibility.